NBTX 001

Drug Profile

NBTX 001

Alternative Names: NBTX-001

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator McLean Hospital
  • Developer McLean Hospital; Nobilis Therapeutics
  • Class Elements; Nootropics
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease
  • Preclinical Post-traumatic stress disorders
  • No development reported Panic disorder

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Panic-disorder in Russia (Inhalation)
  • 14 Jun 2017 Efficacy and safety data from a clinical trial in Panic disorder released by Nobilis Therapeutics
  • 14 Jun 2017 Nobilis Therapeutics plans clinical trials for Psychiatric disorders and Neurodegenerative disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top